Applied Therapeutics, INC

Applied Therapeutics, Inc. has been acquired by Cycle Group Holdings Limited for approximately $14.3 million, with shareholders receiving cash and contingent value rights.

Applied Therapeutics agrees to be acquired by Cycle Group Holdings for $0.088 per share in cash plus contingent value rights tied to drug development and sales milestones, alongside an $8.5 million unsecured loan.

Applied Therapeutics, Inc. has initiated a comprehensive review of strategic alternatives to maximize shareholder value, alongside a significant workforce reduction.

Applied Therapeutics reported a significantly reduced net loss in Q3 2025, alongside ongoing regulatory discussions for govorestat in rare diseases and a board leadership change.

Applied Therapeutics, Inc. has entered into a new 'at-the-market' equity offering agreement with Cantor Fitzgerald & Co. for up to $75 million, replacing a prior agreement.

Applied Therapeutics, Inc. received an additional 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, resulting in a transfer to the Nasdaq Capital Market.

Applied Therapeutics reports significant Q3 2025 net loss and ongoing liquidity concerns, alongside legal settlements and regulatory challenges for its lead drug candidates.

Applied Therapeutics reports significant losses and a going concern warning following FDA rejection of its lead drug for Classic Galactosemia and ongoing litigation.

Applied Therapeutics faces ongoing regulatory hurdles and leadership transitions while reporting a net loss of $21.8 million for Q1 2025.

Applied Therapeutics reports a net loss of $68.6 million for Q3 2024, while highlighting progress in its clinical programs and regulatory submissions.

Applied Therapeutics reports a net income of $2.9 million for the second quarter of 2024, a significant turnaround from a net loss of $29.6 million in the same period last year, driven by changes in warrant liabilities.

Applied Therapeutics reports a net loss of $83.9 million for Q1 2024, but secures $113.8 million in net proceeds through financing activities.

Applied Therapeutics receives a Complete Response Letter from the FDA for its Galactosemia drug, prompting a strategic shift towards Sorbitol Dehydrogenase (SORD) Deficiency treatment.

Applied Therapeutics' 2023 10-K filing highlights advancements in their pipeline, including regulatory submissions for AT-007 and positive trial results for AT-001.

A director of Applied Therapeutics, Inc. reported changes in beneficial ownership following the company's merger, converting shares and options into cash and contingent value rights.

Applied Therapeutics' Chief Commercial Officer, Corwin Dale Hooks, disposed of all common stock holdings following the company's merger, receiving cash and contingent value rights.

Applied Therapeutics' COO, Constantine Chinoporos, reported the disposition of all his common stock and RSUs following the company's merger with Cycle Group Holdings Limited.

Applied Therapeutics director Jay S. Skyler reports zero beneficial ownership of common stock and options following the company's merger with Cycle Group Holdings Limited and AT2B, INC.

Applied Therapeutics' CFO Leslie D. Funtleyder reported significant share and option dispositions following the company's merger with AT2B, INC., receiving $0.088 per share plus a contingent value right.

Applied Therapeutics' Chief Medical Officer, Evan Prescott Bailey, disposed of all common stock and had out-of-the-money stock options cancelled as part of the company's merger with Cycle Group Holdings Limited.

Applied Therapeutics is holding its annual meeting on June 9, 2025, seeking stockholder votes on director election, auditor ratification, executive compensation, and a reverse stock split.

Applied Therapeutics is asking stockholders to approve a reverse stock split at its annual meeting on June 9, 2025, to regain compliance with Nasdaq listing requirements.

Applied Therapeutics, Inc. has filed a definitive proxy statement with the U.S. Securities and Exchange Commission.

Applied Therapeutics is holding its annual stockholder meeting on June 6, 2024, to vote on director elections, auditor ratification, an increase in authorized shares, and other matters.

Propel Bio Management, Leen Kawas, and Richard Kayne, along with Propel Bio Partners, have filed an amendment to their Schedule 13G, reporting a 4.17% beneficial ownership in Applied Therapeutics, Inc.

Alexandria Real Estate Equities and its subsidiaries have updated their beneficial ownership in Applied Therapeutics, Inc., reporting a combined stake primarily through warrants.

T. Rowe Price Investment Management, Inc. has disclosed a beneficial ownership of 14.9% in Applied Therapeutics Inc., holding 21,403,300 common shares as of September 30, 2025.

T. Rowe Price Investment Management, Inc. has reported a significant beneficial ownership stake of 13.2% in Applied Therapeutics Inc., holding 18,683,990 shares.

The Vanguard Group has filed an amended Schedule 13G, revealing a 3.34% beneficial ownership stake in Applied Therapeutics Inc. as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 3.7% beneficial ownership stake in Applied Therapeutics Inc., held as a passive investment.